LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Home・Listă Acțiuni・Cogent Biosciences Inc

Cogent Biosciences Inc

Închisă

35.74 -1.87

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

35.53

Maxim

37.1

Indicatori cheie
By Trading Economics
Venit	-22M -102M
Angajați	258
EBITDA	-30M -109M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+41.85% upside

Dividende
By Dow Jones
Următoarele câștiguri	4 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	666M 6.3B
Deschiderea anterioară	37.61
Închiderea anterioară	35.74

Scor tehnic

By Trading Central

Încredere

Bearish Evidence

4.88 / 5.87 Suport & Rezistență

Cogent Biosciences Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

6 mai 2026, 23:41 UTC

Câștiguri

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6 mai 2026, 21:40 UTC

Câștiguri

Nutrien Logs Higher Profit, Sales Growth in 1Q

6 mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6 mai 2026, 23:34 UTC

Market Talk

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6 mai 2026, 23:13 UTC

Câștiguri

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6 mai 2026, 23:13 UTC

Câștiguri

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6 mai 2026, 23:12 UTC

Câștiguri

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6 mai 2026, 23:11 UTC

Câștiguri

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6 mai 2026, 23:11 UTC

Câștiguri

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6 mai 2026, 23:11 UTC

Câștiguri

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6 mai 2026, 23:11 UTC

Câștiguri

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6 mai 2026, 23:11 UTC

Câștiguri

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6 mai 2026, 23:11 UTC

Câștiguri

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6 mai 2026, 23:07 UTC

Câștiguri

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6 mai 2026, 23:06 UTC

Câștiguri

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6 mai 2026, 23:06 UTC

Câștiguri

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6 mai 2026, 23:05 UTC

Câștiguri

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6 mai 2026, 23:04 UTC

Câștiguri

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6 mai 2026, 22:50 UTC

Câștiguri

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6 mai 2026, 22:25 UTC

Market Talk

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6 mai 2026, 22:11 UTC

Câștiguri

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6 mai 2026, 22:11 UTC

Câștiguri

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6 mai 2026, 22:05 UTC

Market Talk

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6 mai 2026, 21:58 UTC

Câștiguri

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 mai 2026, 21:47 UTC

Market Talk

Câștiguri

Costco Posts 13% Sales Growth in April -- Market Talk

6 mai 2026, 21:46 UTC

Câștiguri

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6 mai 2026, 21:40 UTC

Câștiguri

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 mai 2026, 21:35 UTC

Market Talk

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6 mai 2026, 21:32 UTC

Acțiuni populare

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6 mai 2026, 21:29 UTC

Câștiguri

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Comparație

Modificare preț

Cogent Biosciences Inc Așteptări

Obiectiv de preț

By TipRanks

41.85% sus

Prognoză pe 12 luni

Medie 52.1 USD 41.85%

Maxim 64 USD

Minim 35 USD

În baza a 11 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCogent Biosciences Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

11 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 11 analiști care au acordat evaluări ale acțiunilor Cogent Biosciences Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

4.88 / 5.87Suport & Rezistență

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.